Gene therapy, considered to be the most efficient and sometimes only treatment option for many severe and life-threatening diseases, is shifting to more common indications with higher numbers of patients including Parkinsons and Alzheimers disease. This is where the new ELEVECTA® AAV producer cell lines come into play. ELEVECTA® is a revolutionary technology that enables viral vector manufacturing in an industry-standard, scalable suspension format.